Intravitreal Anti-VEGF Injection Transitions Across Bevacizumab, Biosimilar, and Branded Medications: The IRIS Registry Study. [PDF]
Berkowitz ST +8 more
europepmc +1 more source
Which drugs will Medicare negotiate next? Predicting selected drugs for Initial Price Applicability Year 2029. [PDF]
Li KH, Cousin EM, Sullivan SD.
europepmc +1 more source
BIOSIMILARS IN ONCOLOGY – PART I: THE PRINCIPLES OF BIOSIMILARS
Moorkens, Evelien +4 more
openaire +2 more sources
From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars. [PDF]
Krishnan A +5 more
europepmc +1 more source
Improving engraftment in autologous hematopoietic stem cell transplantation: comparing pegfilgrastim with filgrastim in an outpatient setting. [PDF]
Gutierrez-Aguirre CH +9 more
europepmc +1 more source
Immune-Mediated Inflammatory Diseases: Addressing Safety Concerns and Enhancing the Accessibility of Biosimilars. [PDF]
Feiteira CP, Tavares IC, Ribeiro MHL.
europepmc +1 more source
Response to "Interpreting bone turnover responses and treatment persistence with once-weekly teriparatide". [PDF]
Gu J, Zhao Q, Zhang X, Zhang Z.
europepmc +1 more source
Biosimilar Nivolumab-Based Combination Therapy in Advanced Oral Cavity Squamous Cell Carcinoma: A Real-World Case Series of Five Patients. [PDF]
Meedimale S +3 more
europepmc +1 more source
Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D.
Castle G +5 more
europepmc +1 more source

